

Early Start, Maximum Impact: Long-term Trial Data Supporting Cumulative Clinical Benefit in Children Who Initiated Vosoritide <2 Years Old

Ravi Savarirayan¹, Carlos Bacino², Ricki S. Carroll³, Julie E. Hoover-Fong⁴, Melita Irving⁵, William Wilcox⁶, Claire Milligan⁷, Swati Mukherjee⁷, Richard Rowell⁸, Ian Sabir⁷, Alice Huntsman-Labed⁷, Lynda E. Polgreen⁹

¹Murdoch Children's Research Institute, Royal Children's Hospital, and University of Melbourne, Parkville, Victoria, Australia; ²Baylor College of Medicine, Houston, TX, USA; ³Nemours Children's Hospital, Wilmington, DE, USA; ⁴Johns Hopkins University, Baltimore, MD, USA; ⁵Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK; ⁶Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; ⁷BioMarin (UK) Ltd, London, UK; ⁸BioMarin Pharmaceutical Inc., Novato, CA, USA; ⁹Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

Introduction

- Achondroplasia is a rare skeletal dysplasia caused by diminished endochondral bone ossification that hinders early growth and often results in multisystem complications^{1,2}
- Vosoritide, a first-in-class recombinant C-type natriuretic peptide analog, targets impaired endochondral bone growth and is approved to treat achondroplasia from birth in the US²
 - To maximize clinical benefit, guidelines recommend early, continuous treatment with vosoritide²
- Here, we present 4-year outcomes from CANOPY ACH-EXT (111-208, NCT03989947) to assess durability and breadth of benefit in children who initiated treatment aged <2 years and estimated cumulative height gain for children treated from 0.5 years old until age 16 years for females and 18 years for males

Methods

- CANOPY ACH-EXT includes study 111-208, which is an ongoing, open-label extension of the phase 2 CANOPY ACH-2I (111-206)³ study, a randomized, double-blind, placebo-controlled trial
- Safety, adherence, and efficacy endpoints (**Table 1**) for CANOPY ACH-EXT are presented from participants who were aged <2 years at treatment initiation and with ≥4 years of treatment (111-208)

Table 1. CANOPY ACH-EXT study endpoints

Study	Endpoints	Statistical analyses	Statistical comparator datasets
111-208	Height	Baseline-adjusted cross-sectional comparative analysis	Hoover-Fong et al 2021 (CLARITY) ⁴
	Height Z-score (CDC-referenced ⁵)	Baseline-adjusted cross-sectional comparative analysis	Hoover-Fong et al 2021 (CLARITY) ⁴
	Height Z-score (achondroplasia-referenced ⁶)	Descriptive summary statistics	
	Upper-to-lower body ratio	Longitudinal analysis of covariance model tested paired differences	Del Pino et al 2018 ⁶
	Arm span	Descriptive summary statistics	
	Arm span-to-height ratio	Descriptive summary statistics	
111-208 111-302 ^a	BMI	Baseline-adjusted cross-sectional analysis	Observational/placebo data (vosoritide clinical program) and CrescNet ⁷
	Estimated cumulative height gain beyond natural history	- Difference between mean AGV in treated vs untreated children per annual interval by age and sex⁴ - Sum of height gain at all age intervals - Bootstrapping for 95% CI	

Z-scores were normalized to age- and sex-matched children of average stature (CDC)⁵ or untreated children with achondroplasia.⁴ All comparators were age- and sex-matched untreated children with achondroplasia.^{4,7,8} ^aData from children aged 5 to <18 years at treatment initiation in study 111-302 were used for this analysis. AGV, annualized growth velocity; BMI, body mass index; CDC, US Centers for Disease Control and Prevention; CI, confidence interval.

Results

Participants and treatment adherence

- Of the 33 participants who enrolled in 111-208 aged <2 years, 11 were <0.5 years of age and 22 were 0.5 to <2 years of age at treatment initiation (**Table 2**)
- As of August 2025, at least 4 years after treatment initiation, treatment adherence remained high (**Table 2**)

Table 2. Participant baseline characteristics, study disposition, and treatment adherence

	<0.5 years (n = 11)	0.5 to <2 years (n = 22)
Sex, n (%)		
Male	5 (45.5)	11 (50.0)
Female	6 (54.5)	11 (50.0)
Growth parameters		
BMI Z-score (ACH-referenced), mean ± SD	0.5 ± 0.9	0.1 ± 1.1
Height, cm, mean ± SD	56.8 ± 2.0	69.1 ± 4.2
AGV, cm/year, mean ± SD	22.0 ± 3.9	10.9 ± 3.6
Height Z-score (ACH-referenced), mean ± SD	-0.1 ± 0.5	0.5 ± 0.7
Discontinuations ^a	3 (27.3)	5 (22.7)
Treatment duration, years, mean ± SD	4.5 ± 0.8	4.8 ± 1.5
Adherence, %, mean ± SD	94.8 ± 7.6	97.3 ± 4.3

All data presented as n (%) unless otherwise specified. ^aReasons for treatment discontinuation were adverse event (1 [9.1%] in the <0.5 years group), lost to follow-up, participant's request, and other. ACH, achondroplasia; AGV, annualized growth velocity; BMI, body mass index; SD, standard deviation.

Safety

- Long-term safety remained manageable and predictable (**Table 3**)

Table 3. Summary of AEs

	<0.5 years (n = 11)	0.5 to <2 years (n = 22)
Total treatment exposure, person-years	53.19	105.75
Number of AEs	479 (9.006)	777 (7.347)
AEs leading to study-drug or study discontinuation	2 (0.038)	0
AEs leading to study discontinuation	0	0
Number of SAEs	9 (0.169)	5 (0.047)
SAEs leading to study-drug or study discontinuation	1 (0.019)	0
AEs of special interest		
Injection-site reaction ^a	16 (0.301)	15 (0.142)
Fracture	0	0
Hypotension	2 (0.038)	0

The number of events and event rates per person-year are reported. ^aExcluding bruising and lasting ≥24 hours. AE, adverse event; SAE, serious AE.

Efficacy

- At year 4, gains in height and height Z-score (US Centers for Disease Control and Prevention-referenced⁵) continued to increase compared with untreated children with achondroplasia (**Table 4**)


Table 4. Linear growth

	<0.5 years (n = 11)	0.5 to <2 years (n = 22)
Comparative cross-sectional analyses vs untreated at year 4	n = 9	n = 14
Height gain, cm, mean difference (95% CI)	2.8 (1.2, 4.5)	4.7 (2.8, 6.6)
P-value	0.004	0.0002
Height Z-score (CDC-referenced), mean difference (95% CI)	0.9 (0.3, 1.4)	0.8 (0.4, 1.2)
P-value	0.006	0.0008

CDC, US Centers for Disease Control and Prevention; CI, confidence interval; SD, standard deviation.

- Height Z-scores referenced to untreated children with achondroplasia continued to increase over time (**Figure 1**)

Figure 1. Height Z-scores (achondroplasia-referenced) over time



Estimated additional height gain

- The impact of vosoritide on AGV is consistent regardless of time on treatment across ages (**Figure 2**), allowing AGV to be pooled across CANOPY ACH-EXT studies^{1,3}
- AGV approached that observed in an average stature population for the years after infancy (**Figure 3**)

Figure 2. AGV vs age and years on vosoritide treatment






Figure 3. Mean 6- or 12-month interval AGV by age



- Additional cumulative height gain beyond natural history was estimated for treatment with vosoritide beginning at 0.5 years of age using pooled AGV results from CANOPY-EXT (**Figure 3**) as the sum of height gain at all age intervals (**Figure 4**)
 - The estimated cumulative height gain (95% confidence interval [CI]) compared with untreated children with achondroplasia if continuously treated from 6 months to 18 (males) or 16 (females) years of age was 24.38 (21.22, 27.50) cm and 20.65 (17.78, 23.56) cm, respectively

Figure 4. Estimated cumulative height gain beyond natural history if treatment begins at 0.5 years



Body proportionality and body mass index (BMI)

- Vosoritide-treated children had improved upper-to-lower body ratio (ULBR) I east squares mean (95% CI) of the paired difference vs modeled untreated achondroplasia data.⁶ Paired difference is the ULBR change from baseline in treated participants minus ULBR change based on age and sex matched 50th percentile from the modeled del Pino data.⁹ Those who initiated vosoritide treatment earlier had better ULBR over time (**Figure 5**)

Figure 5. ULBR LSM paired difference vs modeled untreated achondroplasia data

Time point	Age at treatment initiation	Number of participants	Upper-to-lower body segment ratio
Year 1			
<0.5 years	10		$P = 0.0005$
0.5 to <2 years	21		$P = 0.042$
Year 2			
<0.5 years	9		$P = 0.0018$
0.5 to <2 years	21		$P < 0.0001$
Year 3			
<0.5 years	10		$P < 0.0001$
0.5 to <2 years	21		$P < 0.0001$
Year 4			
<0.5 years	9		$P < 0.0001$
0.5 to <2 years	14		$P = 0.0003$

Untreated children with achondroplasia comparator data are from Del Pino 2018 modeled data.⁶ CI, confidence interval; LSM, least squares mean; ULBR, upper-to-lower body ratio.

- Over 4 years of follow-up, arm span continued to increase while arm span-to-height ratio remained stable across years of treatment (**Table 5**)
- Following 4 years of treatment, BMI significantly improved compared with untreated children with achondroplasia (**Table 5**)

Table 5. Arm span and BMI changes from baseline at year 4

	<0.5 years (n = 9)	0.5 to <2 years (n = 14)
Arm span, cm, change from baseline, mean ± SD	24.4 ± 2.7	22.2 ± 3.0
Arm span-to-height ratio, change from baseline, mean ± SD	-0.004 ± 0.031	0.003 ± 0.026
Comparative cross-sectional analysis vs untreated at year 4		
BMI, kg/m ² , mean difference (95% CI)	-1.3 (-2.6, -0.01)	-1.8 (-2.7, -0.9)
P-value	0.0492	0.0006

BMI, body mass index; CI, confidence interval; SD, standard deviation.

Conclusions

- Vosoritide continues to have a manageable safety profile and remains well tolerated with long-term treatment
- Efficacy of vosoritide based on AGV remains consistent, and all other endpoints continued to improve
- Estimated cumulative height gains beyond natural history increase with extended treatment duration
- Early treatment initiation has a positive impact on height and body proportionality and body composition, which may improve functional independence and lower surgical burden
- To maximize benefits, treatment with vosoritide should begin early and continue while growth potential exists
- Data presented here are a part of BioMarin's confirmatory evidence package intended to support conversion to full approval of vosoritide in the United States

References

1. Savarirayan R, et al. *Lancet Child Adolesc Health*. 2024;8(11):40–50. 2. Savarirayan R, et al. *Net Rev Endocrinol*. 2025;21:314–36. 3. Savarirayan R, et al. *Lancet*. 2020;395(10252):684–92. 4. Hoover-Fong J, et al. *Genet Med*. 2021;23:1488–1505. 5. US Centers for Disease Control and Prevention. CDC growth charts. National Center for Health Statistics. Accessed January 29, 2026. https://www.cdc.gov/growthcharts/clinical_charts.htm. 6. Del Pino M, et al. *J Pediatr Endocrinol Metab*. 2018;31(4):451–58. 7. Peel M, et al. *Orphanet J Rare Dis*. 2022;17:228. 8. Prader A, et al. *Rev Pediatr Assoc Supl*. 1989;52:1–125.

Acknowledgments

We thank all trial participants, their families, study-site staff, and investigators. Medical writing support was provided by Morgan Engelhart Wynn, PhD, of Reed-Nucleus, and funded by BioMarin Pharmaceutical Inc. Project management support was provided by Justin Polczak, PhD, of BioMarin Pharmaceutical Inc.

Disclosures

RB has received consulting fees and travel support from Ascendis, BioMarin Pharmaceutical Inc., and QED Therapeutics and has participated as a clinical trial investigator for Ascendis, BioMarin Pharmaceutical Inc., QED Therapeutics, and Sanofi. CB has received consulting fees from BioMarin Pharmaceutical Inc. and has participated as a clinical trial investigator for Ascendis, BioMarin Pharmaceutical Inc., and Roche. RBC has participated as a clinical trial investigator for Ascendis, BioMarin Pharmaceutical Inc., Pfizer, and QED. JEH-F has participated in advisory boards and served as a consultant for Ascendis, AstraZeneca, BioMarin Pharmaceutical Inc., Children's Mercy Research Institute, Medscape, Pfizer, QED Therapeutics, and Tachyon and has received research support from AstraZeneca, BioMarin Pharmaceutical Inc., and QED Therapeutics. MI has received consulting fees from Ascendis, BioMarin Pharmaceutical Inc., QED Therapeutics/Bridge Bio, Sanofi, and Tyra, has participated as a clinical trial investigator for Ascendis, BioMarin Pharmaceutical Inc., and QED Therapeutics/Bridge Bio, has received speaker fees from Ascendis, BioMarin Pharmaceutical Inc., Janssen, QED Therapeutics/Bridge Bio, and Sandoz, and has received travel support from Ascendis, BioMarin Pharmaceutical Inc., and QED Therapeutics/Bridge Bio. WW has received consulting fees from BioMarin Pharmaceutical Inc. and has participated as a clinical trial investigator for BioMarin Pharmaceutical Inc. CM, SM, IS, and AHL are employees and stockholders of BioMarin (UK) Ltd. RR is an employee and stockholder of BioMarin Pharmaceutical Inc. LEP has received honoraria from BioMarin Pharmaceutical Inc., participated on an advisory board for RegenXBio, and consulted for BioMarin Pharmaceutical Inc. and Denali.

To view a copy of this poster, scan this QR code. Copies of this poster obtained through the QR code are for personal use only and may not be reproduced without permission from the authors.

